A PROGNOSTIC SCORING MODEL FOR PATIENTS TREATED WITH AZACITIDINE FOR MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIAS

EHA Library, Kazuya Sato, 132769

THE IMPORTANCE OF IMMUNOPHENOTYPING OF HEMOPOIETIC PRECURSORS IN THE DIAGNOSIS OF CHILDHOOD MDS

EHA Library, Irene Lorand-Metze, 132770

FAVORABLE OUTCOMES WITH TUMOR BURDEN REDUCTION WITH HYPOMETHYLATING AGENTS BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLNATATION FOR PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME

EHA Library, Sungwoo Park, 132771

DISCONTINUATION OF HYPOMETHYLATING AGENT, DOES IT BRING REDUCED SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME ?

EHA Library, Ho Sup Lee, 132772

HETEROGENEITY IN CYTOGENETIC AND CLINICAL FEATURES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND DELETION 5Q

EHA Library, Eleni Gavriilaki, 132773

VALUE OF THE MULTIPARAMETRIC FLOW CYTOMETRY IN LOW RISK MYELODYSPLASTIC SYNDROMES AND TYPE I CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Marcelo Iastrebner, 132774

СLINICAL AND HEMATOLOGICAL FEATURES OF PRIMARY MYELODYSPLASTIC SYNDROMES IN ADULTS AND CHILDREN

EHA Library, Natallia Klimkovich, 132775

IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?

EHA Library, Erden Atilla, 132776

CLINICAL CHARACTERISTICS OF PATIENTS WITH MYELOID NEOPLASMS FROM REGIONS CONTAMINATED BY DEPLETED URANIUM: 20 YEAR ANALYSIS

EHA Library, Amina Kurtovic-Kozaric, 132777

CLINICAL AND LABORATORIAL CHARACTERISTICS OF A COHORT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND ERYTHROID HYPERPLASIA

EHA Library, Aining Sun, 132778

TP53 GENE MUTATIONS IMPACT ON OVERALL SURVIVAL OF PATIENTS TREATED WITH LOW-DOSE CLOFARABINE AS A SECOND LINE THERAPY DUE TO THEIR RESISTANCE TO AZACITIDINE

EHA Library, Thomas Braun, 132779

REPORT ON OUTCOME OF HYPOMETHYLATING THERAPY WITH ANALYSIS ON PROGNOSTIC VALUE OF REVISED-INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OF LOWER-RISK BASED ON IPSS

EHA Library, Yoo Jin Lee, 132780

SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY) SUBANALYSIS: IMPACT OF COMORBIDITIES AND CENTER LEVEL ON RESPONSE TO ESAS IN LOWER RISK MDS

EHA Library, Julio Davila Valls, 132781

IN MULTIPLE MYELOMA THERE ARE TWO SUBSETS OF IMMUNOSUPPRESSIVE POLYMORPHONUCLEAR NEUTROPHILS WITH INCREASED LEVELS OF ARGINASE

EHA Library, Alessandra Romano, 132782

RESISTANCE TO PROTEASOME INHIBITORS IS MEDIATED BY AN OVER-ACTIVATION OF THE UPR AND THE DNA DAMAGE RESPONSE IN A PRECLINICAL MODEL OF MM

EHA Library, Enrique M Ocio, 132783

DEREGULATION OF A-TO-I RNA EDITING IS FUNCTIONALLY AND CLINICALLY RELEVANT IN MULTIPLE MYELOMA

EHA Library, Phaik Ju Teoh, 132784

TARGETING PROTEIN KINASE CK1A IN THE BONE MARROW MICROENVIRONMENT: A NEW POSSIBLE THERAPEUTIC APPROACH FOR MULTIPLE MYELOMA THERAPY?

EHA Library, Marilena Carrino, 132785

RHOU GTPASE: A NOVEL POTENTIAL TARGET TO DISRUPT MULTIPLE MYELOMA PLASMA CELL INTERACTION WITH PROTECTIVE BONE MARROW NICHES

EHA Library, Sara Nunes, 132786

DEREGULATION OF MAJOR DNA REPAIR MECHANISMS CORRELATES WITH CLINICAL OUTCOME OF ANTI-MYELOMA THERAPY. THE BENEFICIAL EFFECT OF DNA REPAIR INHIBITION

EHA Library, Maria Gkotzamanidou, 132787

BAX ACTIVATION IS A POTENTIAL BIOMARKER OF RESPONSE TO FILANESIB (ARRY-520) ALONE AND IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE

EHA Library, Enrique M Ocio, 132788

COMBINATION DRUG THERAPIES WITH THE NOVEL RNA POLYMERASE I INHIBITOR CX-5461 IMPROVE EFFICACY IN THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Kylee Maclachlan, 132789

CHARACTERIZATION OF A PERK KINASE INHIBITOR WITH ANTI-MYELOMA ACTIVITY

EHA Library, Efstathios Kastritis, 132790

EXPLORING THE BONE MARROW NICHE IN MULTIPLE MYELOMA USING AN ADHESION-INDEPENDENT THREE-DIMENSIONAL CO-CULTURE MODEL

EHA Library, Johannes Moritz Waldschmidt, 132791

ACTIVATION OF TOLL-LIKE RECEPTOR 4 PROMOTES MULTIPLE MYELOMA CELL GROWTH AND SURVIVAL THROUGH UPR PATHWAY AND IN A CASPASE-DEPENDENT MANNER.

EHA Library, Efstathios Kastritis, 132792

LONG NON-CODING RNA MALAT1 WAS ASSOCIATED WITH PROGRESSION OF MULTIPLE MYELOMA AND INDUCED BY CELLULAR STRESS

EHA Library, Hiroshi Handa, 132793

COMBINATION OF T(4;14), DEL(17P13), DEL(1P32) AND 1Q21 GAIN FISH PROBES IDENTIFIES CLONAL HETEROGENEITY AND ENHANCES DETECTION OF ADVERSE CYTOGENETIC PROFILES IN 233 NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Thomas Smol, 132794

EXPRESSION OF HUMAN CRBN SENSITIZES MOUSE MULTIPLE MYELOMA CELLS TO LENALIDOMIDE

EHA Library, Dilan Serdar, 132795

INFLUENCE OF HISTONE DEACETYLASE INHIBITORS (HDACIS) ON THE EXPRESSION OF ADHESION MOLECULES AND MODERN TARGET STRUCTURES IN MULTIPLE MYELOMA (MM)

EHA Library, Stefan Müller, 132796

HEME OXYGENASE 1 (HO-1) PROTECTS MYELOMA CELLS AGAINST BORTEZOMIB THROUGH NUCLEAR TRANSLOCATION AND REGULATION OF ER STRESS AND AUTOPHAGY PROTEINS

EHA Library, Daniele Tibullo, 132797

ANTI-MYELOMA EFFECT OF CANNABINOIDS

EHA Library, Jose Antonio Perez-Simon, 132798

BONE MARROW ADIPOCYTES PROMOTE MYELOMA CELL PROLIFERATION THROUGH INTERLEUKIN-6 SIGNALLING

EHA Library, Alvin Katumba, 132799

RETROSPECTIVE STUDY OF PARAPROTEINEMIA PREVALENCE AND DEVELOPMENT OF HEMATOLOGICAL MALIGNANCIES IN HBSAG POSITIVE VERSUS HBSAG NEGATIVE PATIENTS

EHA Library, Radha Raghupathy, 132800

PROTEOMIC SIGNATURE PREDICTING COMPLETE RESPONSE TO PAD IN REFRACTORY MULTIPLE MYELOMA PATIENTS QUALIFIED FOR AUTOPBSCT AND VD CONSOLIDATION – MULTICENTER, POLISH MYELOMA CONSORTIUM 001 STUDY

EHA Library, Dominik Dytfeld, 132801

NOTCH PATHWAY AND INTELEUKIN-6 COOPERATE TO SUPPORT MULTIPLE MYELOMA CELL PROLIFERATION

EHA Library, Serena Galletti, 132802

INTEGRATIVE ANALYSIS OF DNA COPY NUMBER, DNA METHYLATION AND GENE EXPRESSION IN MULTIPLE MYELOMA REVEALS ALTERATIONS RELATED TO RELAPSE.

EHA Library, Patryk Krzeminski, 132803

DETAILED FISH PROFILING OF MULTIPLE MYELOMA PATIENTS IDENTIFIES A GROUP OF PATIENTS WITH ONLY SECONDARY CHROMOSOMAL ABERRATIONS

EHA Library, Milena Pantic, 132804

LONG NON-CODING RNAS IN MULTIPLE MYELOMA

EHA Library, Veronika Kubaczková, 132805

NEXT GENERATION FLOW CYTOMETRY IS A RELIABLE TECHNIQUE FOR DETECTING MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS IN COMPLETE REMISSION: A STUDY COMPARING SHORT VS LONG TERM REMISSION

EHA Library, Alessandro Gozzetti, 132806

BONE DISEASE IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE:RESULTS FROM A SCREENED POPULATION-BASED STUDY

EHA Library, Sigrún Thorsteinsdóttir, 132807

COMPENSATORY STRESS PATHWAYS IN MODULATING ER STRESS IN BORTEZOMIB RESISTANT MULTIPLE MYELOMA.

EHA Library, Nicholas Nikesitch, 132808

CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY

EHA Library, Sara Bringhen, 132809

AN ONGOING MULTINATIONAL OBSERVATIONAL STUDY IN MULTIPLE MYELOMA (PREAMBLE): PRELIMINARY REPORT ON PROGRESSION-FREE SURVIVAL

EHA Library, Teresa Zyczynski, 132810

ROBUSTNESS OF THE PROGNOSTIC VALUE OF THE SKY92 MARKER VERSUS FISH MARKERS ACROSS NINE MULTIPLE MYELOMA COHORTS

EHA Library, Martin van Vliet, 132811

DARATUMUMAB MONOTHERAPY COMPARED WITH REAL-WORLD HISTORICAL CONTROL DATA IN HEAVILY PRETREATED PATIENTS WITH HIGHLY REFRACTORY MULTIPLE MYELOMA: AN ADJUSTED TREATMENT COMPARISON

EHA Library, Joris Diels, 132812

IMPACT OF FAMILY HISTORY ON RISK OF PROGRESSION OF MGUS TO MULTIPLE MYELOMA: A POPULATION-BASED STUDY

EHA Library, Kristrún Aradóttir, 132813

The Swedish Multiple Myeloma Registry: Median survival exceeds 7 years in patients 65 years and younger, population-based data on 3,876 multiple myeloma patients diagnosed 2008-2013

EHA Library, Cecilie Hveding Blimark, 132814

CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE: SUBGROUP ANALYSIS OF THE PHASE 3 ENDEAVOR STUDY TO EVALUATE THE IMPACT OF PRIOR TREATMENT ON PATIENTS WITH RELAPSED MULTIPLE MYELOMA

EHA Library, Philippe Moreau, 132815

CARFILZOMIB AND DEXAMETHASONE VS BORTEZOMIB AND DEXAMETHASONE: SUBGROUP ANALYSIS OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA BY BASELINE CYTOGENETIC RISK STATUS (PHASE 3 ENDEAVOR STUDY)

EHA Library, Hartmut Goldschmidt, 132816

INCREASED LEVELS OF SOLUBLE SYNDECAN-1 AND LDH ARE MAJOR PROGNOSTIC FACTORS FOR SUBSEQUENT OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL AFTER A RELAPSE IN MULTIPLE MYELOMA

EHA Library, Xenofon Papanikolaou, 132817

11C- METHIONINE PET SCAN FOR THE DETECTION OF MULTIPLE MYELOMA LESIONS

EHA Library, Rocío Figueroa Mora, 132818

ACY-241, A NOVEL, ORAL TABLET HDAC6 SELECTIVE INHIBITOR COMBINES SAFELY WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (ACE-MM-200 STUDY)

EHA Library, Ruben Niesvizky, 132819

TREATMENT OF PRE-MYELOMA STATES: A CLINICAL DECISION ANALYSIS

EHA Library, David Liu, 132820

PHASE I/IIA CLINICAL STUDY OF AUTOLOGOUS DENDRITIC CELL THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Je-Jung Lee, 132821

ECONOMIC EVALUATION OF CARFILZOMIB+LENALIDOMIDE+DEXAMETHASONE (KRD) VS. LENALIDOMIDE+DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)

EHA Library, Sumeet Panjabi, 132822

CARFILZOMIB AND DEXAMETHASONE VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF THE PHASE 3 ENDEAVOR STUDY BY AGE SUBGROUP

EHA Library, Antonio Palumbo, 132823

TREATMENT AND OUTCOME PATTERNS IN PATIENTS WITH RELAPSED WALDENSTRÖM’S MACROGLOBULINEMIA: DEVELOPMENT OF A LARGE OBSERVATIONAL PAN-EUROPEAN DATA PLATFORM

EHA Library, Christian Buske, 132824

EFFICACY AND SAFETY OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: IMPACT OF PRIOR THERAPY IN THE PHASE 3 TOURMALINE-MM1 STUDY

EHA Library, Maria Victoria Mateos, 132825

PRACTICE PATTERNS AND OUTCOMES IN U.S. PATIENTS (PTS) WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA (RRMM) AND COMORBID RENAL DYSFUNCTION (RD) AND/OR CARDIOVASCULAR DISEASE (CVD)

EHA Library, Candice Yong, 132826

BORTEZOMIB-BASED TREATMENT MAY OVERCOME THE ADVERSE EFFECT OF FOPNL GENOMIC VARIANT ON THE PROGNOSIS OF MULTIPLE MYELOMA

EHA Library, Katalin Piroska Kiss, 132827

HIGH RESPONSE RATES BUT INEFFECTIVE PRE-SELECTION STRATEGIES FOR TREATMENT WITH HDM AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA BETWEEN 65-70 YEARS IN THE NETHERLANDS

EHA Library, Mirian Brink, 132828

SURVIVAL AND TREATMENT PATTERNS IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA (MM) IN A REAL-WORLD SETTING

EHA Library, Roman Hájek, 132829

FC-GAMMA RECEPTOR POLYMORPHISMS AND PROGRESSION-FREE SURVIVAL: ANALYSIS OF THREE CLINICAL TRIALS OF ELOTUZUMAB IN MULTIPLE MYELOMA

EHA Library, Valerie Poulart, 132830

HIGH EXPRESSION OF AF1Q IS AN ADVERSE PROGNOSTIC FACTOR AND A PREDICTION MARKER OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA

EHA Library, Shotaro Hagiwara, 132831

PHASE 1/2 TRIAL OF LENALIDOMIDE IN COMBINATION WITH CYCLOPHOSPHAMIDE AND PREDNISONE (REP) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (REPEAT-STUDY)

EHA Library, Lotte van der Wagen, 132832

MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE: A POOLED SAFETY ANALYSIS OF 3 CLINICAL TRIALS

EHA Library, Philippe Moreau, 132833

MP0250, A BISPECIFIC VEGF- AND HGF-BLOCKING MULTI-DARPIN*, IN COMBINATION WITH BORTEZOMIB IN MULTIPLE MYELOMA: PRECLINICAL RATIONALE AND PHASE 2 STUDY OUTLINE

EHA Library, Michael Stumpp, 132834

CAN CAPILLARY ZONE ELECTROPHORESIS MONITOR DARWINIAN EVOLUTION OF MULTIPLE MYELOMA CLONES?

EHA Library, Pavel Kotoucek, 132835

THE CLINICAL COURSE OF RELAPSED OR REFRACTORY U.S. MULTIPLE MYELOMA (RRMM) PATIENTS RECEIVING TWO OR MORE LINES OF THERAPY

EHA Library, Dorothy Romanus, 132836

PRACTICE PATTERNS AND OUTCOMES IN ELDERLY U.S. PATIENTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Dorothy Romanus, 132837

COMPARISON OF FOUR NEUROPATHY ASSESSMENT SCALES IN EVALUATION OF TREATMENT EMERGENT NEUROPATHY IN NEWLY DIAGNOSED PATIENTS OF MULTIPLE MYELOMA TREATED WITH BORTEZOMIB BASED REGIMEN

EHA Library, Arjun Lakshman, 132838

SERUM B-CELL MATURATION ANTIGEN IS A BIOMARKER FOR PATIENTS WITH B-CELL DISORDERS

EHA Library, James Berenson, 132839

IMPACT OF IMMUNOPARESIS AND ALTERED SERUM FREE LIGHT CHAIN RATIO ON THE PROGRESSION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) IN A DISTRICT GENERAL HOSPITAL IN UNITED KINGDOM.

EHA Library, Buddhika Badugama, 132840

OVERALL SURVIVAL IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA IN THE REAL-WORLD SETTING: A RETROSPECTIVE ANALYSIS OF THE PHAROS REGISTRY IN THE NETHERLANDS

EHA Library, Silvia Verelst, 132841

COMPARISON BETWEEN 8-COLOR MULTIPARAMETER FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING TO DETECT MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS WHO UNDERWENT AUTO-SCT

EHA Library, HIROYUKI TAKAMATSU, 132842

RENAL AND HEMATOLOGIC OUTCOMES OF BORTEZOMIB-BASED TREATMENT IN PATIENTS WITH LIGHT CHAIN DEPOSITION DISEASE

EHA Library, Efstathios Kastritis, 132843

A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE

EHA Library, Antonio Palumbo, 132844

PROSPECTIVE FUNCTIONAL GERIATRIC ASSESSMENT (CF-GA) IN MULTIPLE MYELOMA (MM) PATIENTS (PTS): CHANGES FROM BASELINE (T0) TO FOLLOW UP ASSESSMENT (T1)

EHA Library, Sandra Dold, 132845

IMPROVEMENT OF OVERALL SURVIVAL IN DANISH MULTIPLE MYELOMA PATIENTS AFTER 2008; A POPULATION-BASED STUDY FROM THE DANISH NATIONAL MULTIPLE MYELOMA REGISTRY

EHA Library, Niels Abildgaard, 132846

ASSESSING MYELOMA BONE DISEASE WITH WHOLE-BODY DIFFUSION-WEIGHTED MRI: COMPARISON WITH FDG PET-CT AND ASSESSMENT OF ADC VALUE

EHA Library, Kentaro Narita, 132847

IMPROTANCE CD138 IMMUNOSTAINING FOR ASSESSMENT OF BONE MARROW PLASMA CELL INFILTRATION IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Yoshiaki Usui, 132848

UPDATED RESULTS OF A SYSTEMATIC REVIEW OF THE RELATIVE EFFECTIVENESS OF TREATMENTS IN RELAPSED / REFRACTORY MULTIPLE MYELOMA

EHA Library, Áine Maguire, 132849

DURATION OF THERAPY IN U.S. PATIENTS TREATED FOR RELAPSED / REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD

EHA Library, Dorothy Romanus, 132850

THE SERUM HEAVY/LIGHT CHAIN IMMUNOASSAY SERVES AS AN ADDITIONAL VALUABLE TOOL FOR SENSITIVE PARAPROTEIN ASSESSMENT, RISK STRATIFICATION AND DISEASE MONITORING IN PATIENTS WITH MONOCLONAL GAMMOPATHY

EHA Library, Christine Greil, 132851

ASSESSMENT OF FRAILTY IN A MULTIPLE MYELOMA (MM) SERIES

EHA Library, Eftychia Nikolaou, 132852

OVERALL RESPONSE RATE OF PATIENTS WITH REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE AFTER LENALIDOMIDE FAILURE: INTERIM RESULTS OF THE POSEIDON STUDY

EHA Library, Tobias Dechow, 132853

IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): CHINA CONTINUATION OF TOURMALINE-MM1

EHA Library, Jian Hou, 132854

PROSPECTIVE EVALUATION OF PROGNOSTIC AND PATHOPHYSIOLOGIC IMPLICATIONS OF BLOOD PRESSURE MONITORING AND BARORECEPTOR REFLEX SENSITIVITY (BRS) IN PATIENTS WITH AL AMYLOIDOSIS

EHA Library, Efstathios Kastritis, 132855

PREVALENCE AND PROGNOSTIC IMPACT OF OLIGOCLONAL BANDS IN PATIENTS WITH AL AMYLOIDOSIS

EHA Library, Luis Gerardo Rodríguez-Lobato, 132856

COMPARISON OF PERIPHERAL BLOOD STEM CELL (PBSC) MOBILIZATION WITH G-CSF ALONE VS G-CSF WITH CYCLOPHOSPHAMIDE POST VCD INDUCTION IN MULTIPLE MYELOMA

EHA Library, Chong Chyn Chua, 132857

ROLE OF PET/CT IN PROGNOSTICATING POST-TRANSPLANT OUTCOMES BASED ON A NEW SCORING SYSTEM: RESULTS OF PIPET-M TRIAL

EHA Library, Uday Yanamandra, 132858

THE EFFECT OF LEVEL OF RESPONSE TO TREATMENT ON ASSOCIATED COSTS AND HEALTHCARE RESOURCE UTILIZATION: A RETROSPECTIVE CHART REVIEW STUDY IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Henri Leleu, 132859

SEVERE DECREASE OF BONE MATERIAL STRENGTH IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE PATIENTS DETECTED BY OSTEOPROBE® MICROINDENTATION METHOD.

EHA Library, Alba Gonzalez, 132860

REAL-WORLD PRESCRIBING PATTERNS IN U.S. MULTIPLE MYELOMA (MM) PATIENTS REFRACTORY TO LENALIDOMIDE IN THE FRONT-LINE

EHA Library, Mehul Jhaveri, 132861

DETERMINATION OF PROTHROMBOTIC PHENOTYPE IN PATIENTS WITH MULTIPLE MYELOMA ON IMMUNOMODULATORY THERAPY BY THE CALIBRATED AUTOMATED THROMBOGRAM.

EHA Library, Veronika Shmeleva, 132862

IN MULTIPLE MYELOMA, T REGULATORY CELLS ARE SIGNIFICANTLY REDUCED AFTER TREATMENT WITH LENALIDOMIDE BUT NOT BORTEZOMIB AND CORRELATE WITH THE ACHIEVEMENT OF AT LEAST VERY GOOD PARTIAL RESPONSE

EHA Library, Christina Hadjiaggelidou, 132863

THE IMPACT OF THE TYPE OF MYELOMA-DEFINING EVENT ON EARLY MORTALITY AND SURVIVAL

EHA Library, Rafael Rios-Tamayo, 132864

REVLIMID, BENDAMUSTINE AND PREDNISOLONE (RBP) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE II CLINICAL TRIAL; OSHO – #077

EHA Library, Juliane Beck, 132865

BETTER OUTCOME IN AL AMYLOIDOSIS (ALA) TREATED WITH MULTIPLE MYELOMA-ORIENTED REGIMENS COMPARED WITH CYCLOPHOSPHAMIDE/BORTEZOMIB/DEXAMETHASONE (CYBORD) IN A SINGLE CENTER EXPERIENCE

EHA Library, ANGELO BELOTTI, 132866

PROGNOSTIC SIGNIFICANCE OF THE REVISED INTERNATIONAL STAGING SYSTEM IN MULTIPLE MYELOMA

EHA Library, Jelena Bila, 132867

SHORT SYSTEMIC TREATMENT CONCURRENT WITH INTENSITY-MODULATED RADIOTHERAPY BY TOMOTHERAPY (IMRT) SHOWS IMPROVEMENT OF PROGRESSION-FREE SURVIVAL IN SOLITARY PLASMACYTOMA OF THE BONE (SPB)

EHA Library, Emmanuelle Le Ray, 132868